Genetix launches QPDisplay - new automated phage display system

May 16 2005: Genetix Limited (New Milton, UK) has announced the launch of QPDisplay - a dedicated picking and library management system that increases productivity by improving the reliability, precision and accuracy of the phage display process.

QPDisplay is applied to the critical later stages of antibody development. The new system supports the multi-round bio-panning workflow of picking, re-arraying of positives and ‘cherry picking’ of unique clones. QPDisplay is an integral part of the company’s portfolio of instrumentation for upstream aspects of antibody development and perfectly complements its hybridoma selection and mammalian cell picking systems, ClonePix and ClonePixFL.

The new system was unveiled this week at the Protein Engineering Summit (PEGS) in Boston, USA.

Commenting on the launch, Dr Ian Taylor, Business Manager at Genetix, said:
"Antibody discovery using phage display is a time-sensitive process that generates high-value end products. Colony picking and subsequent clone management are key steps of the phage display process. By increasing accuracy and reliability here, we can have a significant impact on both productivity and timescales.

For many years, Genetix has been recognized as the industry standard within this specific area of phage display research - our platforms are used and recommended by the major commercial library providers.”

Phage display is an established and powerful tool for antibody discovery, optimization and generation. However, there is often a considerable amount of manual work involved in the process. This increases both processing time and the risk of errors.

QPDisplay removes many of the labor-intensive aspects of the work. At the same time, it consolidates all relevant experimental information within an integrated data tracking module. This can then be simply incorporated with higher-level informatics systems.

Further information on the complete range of QP platforms and ClonePix systems is available at www.genetix.com

About Genetix
Genetix Limited provides automated systems for cell biology, and proteomic and genomic research. It supplies many leading academic institutions world-wide and major international companies involved in the drug discovery process including GSK, AstraZeneca and Novartis.

Genetix made a significant contribution to the Human Genome Project by supplying high-throughput equipment to seven of the leading eight laboratories of the consortium. Genetix, through its R&D expertise and scientific resource, is committed to the continual development of innovative solutions to accelerate the rate of global scientific discovery.

Genetix is quoted on the London Stock Exchange (symbol GTX) and is based in New Milton,
Hampshire, UK.

www.genetix.com  

A high resolution image is available from Richard Kent at Kapler Communications –
richard@kapleronline.com  Please quote reference number GEN/PRL/010




Enquiries:
Genetix Ltd
George Hutchinson,
Marketing Manager, Picking and Placing SBU
Tel: +44 (0) 1425 624 600
Email: george.hutchinson@genetix.com  

Media enquiries:

Kapler Communications Ltd
Richard Kent,
Director
Tel: +44 (0) 1480 471 117
richard@kapleronline.com